Member Info for Fardistanthills

I read earlier that this was released over the weekend? Could someone kindly point me to where I can take a look at this. Thanks

Thx PL75, trust me to get it the wrong way around!

The remark AS made about continuing to test negatives to drive thr decimal point was interesting. I believe I am right in saying the better the sensitivity (99% in the original CV?) the fewer the false negatives there will be. Which again if I've got it right, will make AVCT's LFD even better for 'green-lighting.' And the ability to use a test for 'green-lighting' is exactly what airlines and others looking to introduce high quality fast cheap daily sel-testing to keep staff Covid clear will be after. False negatives are the last thing you want in situations where an outbreak amongst staff can critically affect operations. So a good pointer to the sort of use case and differentiator AS expects to derive from having one of (or even the best) test availabale, once validated for self-testing. (I think my thinking is properly thought through?)

I am sure that AVCT are seeking ISO certification. It will be for the chemical processes used in the manufacture of affimers.

Good time to bury adverse reports and reassure that us the UK gov has every confidence in the lateral flow tests used by our NHS?

The cynic in me very much goes along with PL - 10.24 am. But the logic (or illogic) in the mess the UK government seems to be getting into is that goodwill toward it amongst UK diagnostic businesses will be so low they will sell all they can produce elsewhere. Following this argument production capacity might never become sufficient to adequately replace Innova (or cheap Innova clones) with affimer based "sovereign LFDs". Other than at a hefty pemium? The again the cynic in me thinks they prefer the brown envelope approach to paying any sort of premium.

Fantastic day alround - well done Avacta

Thx PL

Oops, bottom right - can't tell my right from my left either!

I see bottom left of the spec sheet Mologic get a mention - too hard to get my simple mind around the reason for that?

I think you're right - full steam ahead PR wise. But will it be that visible? Surely they will be focussing on government health agencies, disgnostic trade organisations, supply chain issues, manufacturing & distribution infrastructure, etc?

AgentB, under the Corona Act 2020 the government took various emergancy powers and I believe these currently run until September. At that point the government can extend the provisions made under this Act for a further 6 months - but I think with the proviso that they are scrutinised by parliament in some way. So I doubt any 21st June relaxations would rule out granting us 'emergancy' home use, as previously given to Innova.

Matml74 page 55 under "Commercial risk - Diagnostics"

I agree AgentB, a pretty damning paragraph

Interesting Europe put before UK in this line from page 18 of yesterday's Annual Report:

"Our focus is on manufacturing and supply of the product post-CE marking and in building the commercial routes to market with partners in Europe and the UK.!

... that incorporate...

From memory the UK has published proposals to set a standard for CV-19 antigen LFTs - to be introduced at the end of this year? One would hope these will be challenging since AVCT has shown the standard can be upped. So in the event the Innova test, being mAb based, cannot meet such a new standard then it would seem possible to me that they would want to use test strips incorporate AVCT's affimer reagent, supplied by whoever is doing the manufacturing of these?

And I think I'm right in saying Cytiva who are capable of supplying test strips, coincidentally have a plant in S Wales.

Maybe Innova is set to be one of the as yet unannounced other manufacturing partners .

All pure speculation.

The rest of the D Tel Article reads:

There are several other companies looking to win lucrative government contracts to supply the NHS with lateral flow tests.

Bedfordshire-based Mologic, which has developed a lateral flow test with the Liverpool School of Tropical Medicine, is waiting to get the green light for its product.

There is understood to be general frustration among many companies over the time it is taking for the government to evaluate these tests.

Mologic's test, if approved, will be manufactured by Scotland's Omega Diagnostics. Omega signed a £374m contract with the government in February to manufacture British-designed lateral flow tests and was hoping to begin making the devices in April.

While it has been working closely with Mologic, Omega will, in theory, manufacture whatever tests the Government tells it to. Shares in Omega have risen more than seven-fold since March last year.

A spokesman for the Department of Health and Social Care said: "We have built the largest testing infrastructure in Europe through partnerships across industry, academia, local government and others.

“The UK is now established as a testing and diagnostics powerhouse, with over 173m tests conducted. Collaboration continues to be a priority and we are hugely grateful to all the manufacturers and suppliers who have offered their assistance in the production of Covid-19 tests.”

My understanding has always been that CE is not 'given. but that it is self declared by the manufacturer and the next step is registration, a step which does not involve seeking permissions of any sort. The 10th May RNS says

"The Group expects to receive confirmation of the registration of the AffiDX(R) in-vitro diagnostic device in the coming days, which will allow the Group to immediately place the test on the market."

I've never been convinced there would be an RNS announcing "confirmation of the registration"? Surely this is just a formality, totally expected and so not material? A bit like completion date is what matters when buying a house and registration at the Land Registry which follows is just a bit of essential tidying up.

So I too think our next RNS re the AffiDX(R) test device is likely to be to do with (large) orders being negotiated/finalised/placed?

But what do I know - compared with how much everyone else seems to know ;-)

Mr A had me worried. Thanks for doing some digging Rb40. This is what my vague recollection - that we might hear something on AVA6000 by year end - was based on too:

"...when we see the first read-out from the AVA6000 trial approximately four months into the dose escalation phase."